Multitrator Spółka z Ograniczoną Odpowiedzialnością (KRS 0000573133, NIP 7010504450) is a Polish company, headquartered in Warszawa, Mazowieckie voivodeship. Multitrator operates in: Research and experimental development on biotechnology (PKD 72.11.Z). Industry: Research and development. The company has been listed in the National Court Register since August 31, 2015. Multitrator's most recently reported net revenue was 444.2 K PLN for 2025.
Negative equity
Negative equity in 3 of 8 available reporting years.
No arrears identified in the analysed sources
No arrears or bankruptcy proceedings identified in the analysed sources.
Business profile - Multitrator
Identity
- Name
- Multitrator Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- August 31, 2015
- Registry status as of
- June 30, 2026
- Latest entry
- June 30, 2026
- Founding act
- 11.08.2015 R., NOTARIUSZ TOMASZ KARŁOWSKI, KANCELARIA NOTARIALNA W WARSZAWIE PRZY UL. INFLANCKIEJ 4, REPERTORIUM A 841/2…
Articles of association history (1)
- August 11, 2015: 11.08.2015 R., NOTARIUSZ TOMASZ KARŁOWSKI, KANCELARIA NOTARIALNA W WARSZAWIE PRZY UL. INFLANCKIEJ 4, REPERTORIUM A 841/2015
Activities
Other activities
Address and contact
- Address
- UL. NOWOGRODZKA, 18A, 16, 00-511, WARSZAWA, POLSKA
- Voivodeship
- MAZOWIECKIE
- District
- WARSZAWA
- BIURO@MULTITRATOR.EU
- Website
- WWW.MULTITRATOR.EU
- E-delivery address
- AE:PL-50721-51558-EUBDE-15
Risk and payment profile - Multitrator
Credibility rating
47 / 100
Average credibility
Insolvency risk
Very low
Low threat
Closure risk
4
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organisational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
1
1/11 yrs
Board changes
0
0/11 yrs
PKD changes
0
0/11 yrs
Name changes
0
0/11 yrs
Data from 11 years of registry activity.
Credibility history
Payment reliability score from 2018–2025
Current: D (47/100)
Trend: deteriorating (-5.9 pts/year)
Słaba wiarygodność płatnicza – wskaźniki finansowe sugerują podwyższone ryzyko opóźnień lub niewykonania zobowiązań.
Trade credit limit history
Standard limit from 2018–2025
Current: 9.4 K PLN
Safe: 2.8 K PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - Multitrator
Founded
August 31, 2015
10 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
WARSZAWA
MAZOWIECKIE
Primary PKD
72.11.Z
Research and experimental development on biotechnology
Share capital
50.0 K PLN
1,000 shares total
Shareholders
2
shareholders
Board
1 person
Filed years
8 years
2018–2025 · profitable: 4/8
Registry entries
34
latest: June 30, 2026
Risk signals
Revenue
444.2 K PLN
2025
Net profit
-35.1 K PLN
2025
Assets
216.1 K PLN
2025
Equity
150.6 K PLN
2025
Valuation
115.2 K PLN
Low confidence
Low confidence
Companies in the same location
EU Funds
Projects co-financed by the European Union for Multitrator - total value, EU contribution and the company's largest awards.
Projects
3
EU co-financing
509.5 K PLN
Total project value
797.7 K PLN
Eligible spending
646.0 K PLN
Funds
Operational programmes
- Regionalny Program Operacyjny Województwa Mazowieckiego na lata 2014-2020
Largest projects
Top 3 by EU co-financing
| Project | Fund | EU co-financing | Value | Rate | Period |
|---|---|---|---|---|---|
Mobilna kapsuła mieszkalna do celów turystycznych i kryzysowych |
Public procurement
Trademarks
Reviews
Rate business credibility - Multitrator.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase on BCX-CM-J – potentially Europe's first veterinary cell-therapy drug based on mesenchymal stem cells, for dogs with osteoarthritis. Responses to the EMA's final questions are due in May 2026; a CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. A pre-commercial biotech: it closed 2024 with a PLN 14.9m loss on zero revenue and PLN 33.6m of cash at year-end. Trigon DM maintains a buy rating with a PLN 127.2 price target.
News
Captor Therapeutics: PLN 36m of cash at 30 September 2025, runway to mid-2026 – clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) – a pre-commercial biotech specialising in targeted protein degradation (TPD) – closed Q3 2025 with PLN 36m of cash and grants securing funding to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I, with the first patient dosed at the Barcelona Clinic Liver Cancer. CT-03, an MCL-1 degrader, is close to clinical entry. Without a new R&D partnership or share issue in 2026, the company will need additional financing.
